Conventional type 1 dendritic cells (cDC1) are critical for antitumor immunity, and their abundance within tumors is associated with immune-mediated rejection and the success of immunotherapy. Here, we show that cDC1 accumulation in mouse tumors often depends on natural killer (NK) cells that produce the cDC1 chemoattractants CCL5 and XCL1. Similarly, in human cancers, intratumoral CCL5, XCL1, and XCL2 transcripts closely correlate with gene signatures of both NK cells and cDC1 and are associated with increased overall patient survival. Notably, tumor production of prostaglandin E2 (PGE 2 ) leads to evasion of the NK cell-cDC1 axis in part by impairing NK cell viability and chemokine production, as well as by causing downregulation of chemokine receptor expression in cDC1. Our findings reveal a cellular and molecular checkpoint for intratumoral cDC1 recruitment that is targeted by tumor-derived PGE 2 for immune evasion and that could be exploited for cancer therapy.
INTRODUCTION
The tumor microenvironment (TME) contains stromal cells and immune cells that shape cancer development and impact the response to tumor therapy (Hanahan and Weinberg, 2011; Palucka and Coussens, 2016) . Intratumoral immune cells comprise lymphocytes, such as T cells, B, cells and natural killer (NK) cells, and diverse populations of myeloid cells, including granulocytes, monocytes, macrophages, and dendritic cells (DCs) (Gajewski et al., 2013; Hanahan and Weinberg, 2011; Palucka and Coussens, 2016) . The different myeloid cells within the TME fulfill distinct and sometimes opposing roles. Simplistically, intratumoral monocytes and M2-polarized macrophages can promote cancer cell growth, angiogenesis, and metastasis, as well as contribute to the establishment of an immunosuppressive environment. They are associated with tumor progression and poor clinical outcome (Noy and Pollard, 2014) . In contrast, M1-polarized macrophages and DCs contribute to anti-tumor immunity and are associated with a favorable outcome (Engblom et al., 2016) .
The contribution of conventional DCs (cDCs) to anti-tumor immunity reflects their ability to present tumor antigens and to secrete cytokines that regulate T cell survival and effector function. cDCs can be divided into at least two subsets, conventional type 1 dendritic cells (cDC1) and conventional type 2 dendritic cells (cDC2) (Guilliams et al., 2014; Merad et al., 2013) . The cDC1 subset depends for its development on the transcription factor Batf3 and can be identified by the selective expression of the C-type lectin receptor DNGR-1 (aka CLEC9A) and the chemokine receptor XCR1 and, in non-lymphoid organs and in tumors, additional expression of the integrin aE (CD103) in the presence of low expression of CD11b. cDC1 are especially adept at taking up dead tumor cells and transporting tumor antigens to tumor-draining lymph nodes where they constitute the key DC subtype responsible for cross-priming anti-tumor CD8 + T cells (Roberts et al., 2016; Salmon et al., 2016) . In addition to this trafficking role, cDC1 also play a key role within tumors themselves. Intratumoral cDC1 attract T cells (Spranger et al., 2017) , re-stimulate and expand tumor-specific CD8 + T cells (Broz et al., 2014) , and support T cell effector function by secreting interleukin (IL)-12 (Ruffell et al., 2014) . The overall importance of cDC1 in anti-tumor immunity is underscored by multiple studies demonstrating that the lack of cDC1 in Batf3 À/À mice abolishes the rejection of immunogenic tumors and the response to adoptive T cell therapy and to immune checkpoint blockade (Broz et al., 2014; Hildner et al., 2008; Salmon et al., 2016; Sá nchez-Paulete et al., 2016; Spranger et al., 2015) .
Human cDC1 are very rare within the TME and often excluded from early tumor stages, which might hinder anti-tumor immunity and contribute to cancer progression. Although intratumoral cDC1 have not been investigated in humans in as much detail as in mice, cDC1 abundance in human melanoma correlates with T cell infiltration and the ratio of cDC1-selective transcripts over macrophage-restricted transcripts can be used as a prognostic marker for cancer patient survival (Broz et al., 2014; Spranger et al., 2017) . Therapies aimed at increasing cDC1 abundance in tumors or facilitating their activation may therefore boost anti-tumor immunity and potentially increase the responsiveness of cancer patients to immunotherapy (Broz et al., 2014; Salmon et al., 2016; Spranger et al., 2017) . However, the mechanisms determining the abundance of cDC1 at the tumor site remain enigmatic and it is unclear whether cDC1 are actively recruited into the TME and if this requires the participation of other cell types. Prostaglandin E2 (PGE 2 ) is a prostanoid with immune-regulatory function that is produced by many cell types and can further be released upon cell death (Hangai et al., 2016) . We previously found that many tumors secrete PGE 2 to suppress anti-cancer immunity (Zelenay et al., 2015) . In such tumors, genetic ablation of cyclooxygenases, encoded by the Ptgs1 and Ptgs2 genes, leads to inability to produce PGE 2 and renders the cancers susceptible to cDC1-dependent CD8 + T cell-mediated immune control (Zelenay et al., 2015) . Mouse tumors lacking PGE 2 production are therefore an ideal system in which to dissect the mechanisms underlying cDC1 accumulation. Here, we show that such tumors are infiltrated by cDC1, and we identify a key role for intratumoral NK cells in producing CCL5 and XCL1 chemokines that promote cDC1 recruitment. We provide evidence that a similar NK cell/ chemokine functional axis determines cDC1 abundance in human melanoma, breast cancer, lung cancer, and head and neck squamous cell carcinoma and show that it impacts on patient survival. Finally, we uncover a role for PGE 2 both in diminishing NK cell survival and function and in downregulating cDC1 responsiveness to chemoattractants. These data provide insights into the control of cDC1 accumulation in tumors in mice and humans and support the rational design of therapies aiming to increase cDC1 numbers in tumors that might help overcoming resistance to current immunotherapies.
RESULTS cDC1 Accumulate within the Tumor Microenvironment of COX-Deficient Tumors
We established a flow cytometry staining protocol that allows distinction between cDC1 and other CD11c + MHC class II (MHCII) + myeloid cell populations including CD64 + macrophages and CD11b + cDC2 in tumors ( Figure 1A (Sancho et al., 2008) , XCR1 (Dorner et al., 2009) , and IRF8 (Ginhoux et al., 2009) (Figure 1B ), validating them as bona fide cDC1. We used the staining protocol to assess cDC1 abundance in PGE 2 -producing control (COXcompetent) BRAF V600E and Ptgs1/Ptgs2 À/À (COX-deficient) BRAF V600E melanoma tumors (Zelenay et al., 2015) . We focused initial analyses on 4 days after tumor cell implantation, before the onset of any T cell-mediated immune control of the COXdeficient tumors (Zelenay et al., 2015) . As reported (Zelenay et al., 2015) , control and Ptgs1/Ptgs2 À/À BRAF V600E tumors were broadly equivalent in terms of total number of CD45 + cells, CD11c
+ MHCII + cells, and tumor mass ( Figure 1C ). However,
Ptgs1/Ptgs2
À/À BRAF V600E showed markedly greater accumulation of cDC1, both in frequency and in total numbers ( Figure 1C ) (Zelenay et al., 2015) . Consistent with the flow cytometric analysis, cDC1 were sparse in confocal images of sections from control BRAF V600E tumors but abundant in those from Ptgs1/ Ptgs2 À/À BRAF V600E tumors ( Figures 1D and 1E ). In addition to increased density, cDC1 often formed multicellular clusters within Ptgs1/Ptgs2 À/À BRAF V600E tumor tissue (Figures 1D and 1E) . Tumor infiltration by cDC1s was confirmed by distance analyses after surface reconstruction of cDC1 profiles in confocal images, which revealed that cDC1 in Ptgs1/Ptgs2 À/À BRAF V600E melanomas were located further away from the tumor margin and from CD31 + blood vessels than in control tumors ( Figure 1F ). We extended the analysis to other mouse cancer models and found that, similar to BRAF V600E melanoma, tumors formed by COX-competent but not COX-deficient CT26 colorectal cancer cells or 4T1 breast cancer cells displayed low numbers of intratumoral cDC1 ( Figures S1A-S1D ). Again, we observed altered localization of cDC1 in the COX-sufficient tumors, which displayed fewer clusters of cDC1 deep within the tumor parenchyma (Figures S1A-S1F). Finally, we confirmed that cDC1 recruitment is functionally relevant by demonstrating that immune control of COX-deficient tumors is lost in cDC1-deficient Batf3 À/À mice ( Figure 1G ) (Zelenay et al., 2015) . This loss of control correlated with markedly reduced tumor infiltration by CD8 + T cells ( Figure 1H ) and the fact that the few infiltrating CD8 + T cells, including tissue-resident memory T cells In (C) and (F)-(I): n.s., non-significant, *p < 0.05, **p < 0.0, ***p < 0.001. See also Figure S1 . (TRM) identified by CD103 expression, did not express granzyme B (GzmB) ( Figure 1I ). We conclude that tumor-derived PGE 2 impairs the accumulation and spatial positioning of cDC1 within the TME and that an unknown mechanism induces the accumulation of cDC1 in COX-deficient tumors, which is key for subsequent CD8 + T cell-mediated anti-cancer immunity.
cDC1 Accumulation in COX-Deficient BRAF
V600E
Melanoma Depends on NK Cells In addition to an increase in cDC1 and modest elevation of T cell populations, Ptgs1/Ptgs2 À/À BRAF V600E melanomas showed a prominent early rise in NK1.1 + CD3
À cells (Figure 2A ), which was sustained over several days ( Figure S2A ). NK1.1 + CD3 À cells stained positive for CD49b and GzmB, suggesting that they were conventional NK cells and not ILC1 (Serafini et al., 2015) (Figure S2B) . The distribution of intratumoral NK cells was highly similar to that of cDC1, evident as multicellular clusters of both cell types ( Figure 2B ) located within 5-10 mm of each other (Figure S2C) and with NK cells positioned closer to cDC1 than to other MHCII + cells ( Figure 2C Figure 2H ).
Antibody-mediated depletion of NK cells resulted in rapid growth of Ptgs1/Ptgs2 À/À tumors in WT mice ( Figure 2I ). This was similar to the loss of immune control seen in Batf3 À/À mice but NK cell depletion in the latter further exacerbated tumor growth ( Figure 2I ), arguing that some but not all of the effects of NK cells on tumor control are mediated through cDC1. This might be expected from the fact that NK cells can directly kill tumor cells and produce cytokines with anti-tumor effects (Guillerey et al., 2016) . Taken together, these data suggest that NK cells play a key role in anti-tumor immunity in part but not exclusively by promoting intratumoral accumulation and positioning of cDC1. Data shown in (A) and (F)-(I) are pooled from at least two independent experiments with 4-6 mice per group and represented as mean ± SEM; (A), (C), and (E-I): n.s., non-significant, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2 .
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Signal strength (relative to control tumor) produced CCL5 but expressed only low levels of Xcl1 mRNA ( Figure 3G ). At a later time point (12 days), when T cell infiltration is much more prominent, CCL5 protein was detectable in NK and CD8 + T cells in Ptgs1/Ptgs2 À/À BRAF V600E tumors but Xcl1 mRNA still remained largely restricted to NK cells and was not highly expressed by any T cells, including TRM ( Figures  3H-3J ). Similar observations were made in spontaneously developing mammary tumors in MMTV-PyMT mice ( Figures 3K-3M 4B ). Therefore, in the absence of PGE 2 , intratumoral NK cells are a major source of XCL1 and CCL5. Finally, to examine whether PGE 2 directly impacts NK cell production of CCL5 and XCL1, we isolated splenic NK cells from WT mice and stimulated them through NK1.1, an activatory receptor. Anti-NK1.1 induced secretion of CCL5 and XCL1, which was strongly reduced in a dose-dependent manner in presence of PGE 2 (Figures 4E and 4F) . Survival of NK cells was also markedly reduced by PGE 2 even in the presence of IL-2 ( Figure 4G ). IL-15 or IL-15:15Ra complex was able to rescue NK cell survival but not the impaired CCL5 and XCL1 production ( Figures S4A-S4C ). Similar to splenic NK cells, NK cells isolated from tumors were susceptible to PGE 2 inhibition (Figures 4H and 4I) . Despite its marked effects on function and survival, PGE 2 did not induce the expression of the co-inhibitory receptors TIM-3 and PD-1 by NK cells in vitro (data not shown) or in vivo ( Figure 4J ). These data indicate that NK cells are a direct target of tumor-derived PGE 2 , which decreases cell viability and inhibits production of putative cDC1 chemoattractants.
XCL1 and CCL5 Mediate Recruitment of cDC1 into Tumors to Promote Immune Control cDC1 express XCR1, the only receptor for XCL1 (Dorner et al., 2009) , and CCR1 and CCR5, both of which bind CCL5 (McColl, 2002) . Consistent with that expression pattern, cDC1 generated from bone marrow cells in vitro migrated efficiently toward CCL5 and XCL1 in a transwell assay ( Figure 5A ). To investigate whether the two chemokines are necessary for cDC1 recruitment into tumors, we treated WT mice with neutralizing antibodies against CCL5 (aCCL5) and XCL1 (aXCL1) or isotype-matched control antibodies and implanted them with Ptgs1/Ptgs2 À/À BRAF V600E tumor cells. We found that in vivo blockade of CCL5 and XCL1 resulted in markedly reduced cDC1 accumulation within tumors ( Figure 5B ). These data indicate that cDC1 accumulation in the TME requires CCL5 and XCL1. Single loss of either CCR5 or XCR1 was not sufficient to block intratumoral cDC1 accumulation (data not shown), likely because of receptor redundancy, and we were not able to test mice doubly deficient in the two receptors because of genetic linkage of the loci. Instead, we used gain-of-function experiments to determine whether CCL5 or XCL1 are sufficient to mediate cDC1 recruitment into the TME. Four days after inoculation of WT mice, cDC1 accumulation was significantly increased in Ptgs1/Ptgs2 À/À BRAF V600E tumors retrovirally transduced to express CCL5 or XCL1 compared to tumors formed by mocktransduced (EMPTY) cells ( Figure 5C ). Consistent with increased cDC1 accumulation, Ptgs1/Ptgs2 À/À BRAF V600E tumors expressing CCL5 or XCL1 showed accelerated rejection in WT mice compared to mock-transduced cells ( Figure 5D ) but all grew at a comparable rate in Batf3 À/À mice ( Figure 5E ). The latter indicates that CCL5-or XCL1-expressing tumors are not intrinsically compromised in their ability to grow in vivo but are controlled by the immune system in a cDC1-dependent manner.
In NK cell-depleted mice, Ptgs1/Ptgs2 À/À BRAF V600E tumors expressing XCL1 grew more slowly than mock-transduced cells ( Figure 5F ), suggesting that XCL1-mediated recruitment of cDC1 can partially compensate for the loss of tumor immune control caused by NK cell ablation. Next, we extended this analysis to other tumor models. Similar to Ptgs1/Ptgs2 À/À BRAF V600E tumors, B16-OVA tumors (that do not produce PGE 2 ) (Zelenay et al., 2015) expressing CCL5 and XCL1 showed increased accumulation of cDC1 within the TME ( Figure 5G ) and decreased tumor growth ( Figure 5H ). A similar trend was observed for tumors formed by Ptgs2 À/À CT26 colorectal cancer cells in BALB/c mice (Figures 5I and 5J) . We conclude that cDC1 accumulation within the TME can be induced by the cDC1-recruiting chemokines CCL5 and XCL1 to improve tumor immune control.
PGE 2 Inhibits the Responsiveness of cDC1 to Chemokines
We further investigated whether CCL5 or XCL1 expression also induced cDC1 accumulation in COX-competent tumors, bypassing PGE 2 -mediated suppression of NK cells. Interestingly, neither CCL5 nor XCL1 expression was able to rescue the low abundance of cDC1 in BRAF V600E tumors ( Figure S5A ), which all grew similarly to mock-transduced cells in WT mice ( S5D). Therefore, chemokine expression alone is not sufficient to recruit cDC1 into PGE 2 -producing tumors, suggesting that PGE 2 not only suppresses CCL5 and XCL1 production by NK cells but also impairs cDC1 responsiveness to the chemokines. Consistent with that notion, cDC1 exposed to conditioned medium (CM) from PGE 2 -producing tumors were impaired in their migration toward CCL5 and XCL1 (Figures S5E and S5F) . Furthermore, cDC1 incubated with CM from PGE 2 -producing cells or with synthetic PGE 2 downregulated Xcr1 and Ccr5 mRNA and XCR1 protein ( Figures S5G-S5I ). XCR1 downregulation was also seen in cDC1 isolated from BRAF V600E tumors ( Figure S5J ). These data indicate that PGE 2 can block the ability of cDC1 to migrate toward the chemokines CCL5 and XCL1 in part by inducing downregulation of the respective receptors.
Analysis of Human Cancer Datasets Reveals a Close
Correlation between NK Cells, Chemokines, and cDC1
To determine whether NK cells can similarly serve as a source of XCL1 and CCL5 in humans, we analyzed a gene expression dataset of 38 populations of human hematopoietic cells (Novershtern et al., 2011) . We additionally probed for XCL2, a paralog of XCL1 that is found in humans but not mice and also binds to XCR1 with high affinity (Fox et al., 2015) . Both XCL1 and XCL2 were highly expressed within the CD56 À (often referred to as CD56 dim ) subset of NK cells ( Figure 6A ). CCL5 was expressed in CD56 À and CD56 + NK cells, as well as in other immune cell populations such as effector and memory CD8 + T cells ( Figure 6A ). Therefore, human NK cells can produce the chemokines CCL5, XCL1, and XCL2 and are a rare source of the latter two, at least in blood under steady-state conditions. To investigate the presence of these chemokines in human cancers, we looked at tumor gene expression data from The Cancer Genome Atlas (TCGA). When analyzing TCGA datasets for skin cutaneous melanoma (SKCM, n = 470 patients), breast invasive carcinoma (BRCA, n = 1098), head and neck squamous cell carcinoma (HNSC, n = 528), and lung adenocarcinoma (LUAD, n = 585), we observed a positive correlation between the three chemokines XCL1, XCL2, and CCL5 that was highly significant in each dataset (Figures 6B and S6A) , consistent with the notion that they might all be produced by the same intratumoral cell type. To assess whether that type could be NK cells, we compared a chemokine gene expression signature containing XCL1, XCL2, and CCL5 with a broad signature of NK cells ( Figure S6B ). We observed a highly significant, positive correlation between the two gene signatures in all four TCGA datasets ( Figure 6C ).
Next, we investigated whether cDC1 accumulation in human tumors correlated with the abundance of NK cells and the chemokines. To identify transcripts best suited to identify cDC1, we utilized a recently published gene expression dataset for DC populations in different human tissues (Heidkamp et al., 2016). We derived a human cDC1 signature that included CLEC9A (Poulin et al., 2012) , XCR1 (Bachem et al., 2010; Dorner et al., 2009; Fox et al., 2015) , CLNK, and the transcription factor BATF3 (Robbins et al., 2008) (although the latter was also expressed at low levels in cDC2). We excluded CCR7, THBD (CD141/BDCA3), IRF8, ITGAE (CD103), FLT3, and ZBTB46, which have previously been used as cDC1 markers (Broz et al., 2014; Roberts et al., 2016) but, in our analysis, displayed promiscuous expression ( Figure 6D ). In all cancer types, our cDC1 signature showed a high degree of positive correlation with both the gene signatures for NK cells ( Figure 6E ) and the chemokine signature ( Figure 6F ). The 3-way correlation always reached significance but was most profound in melanoma and breast cancer ( Figure 6G) . A CD8 T cell signature ( Figure S6B ) also correlated with the signatures for cDC1, NK cells, and chemokines , consistent with the notion that the interplay between NK cells and cDC1 favors CD8 + T cell-dependent anti-tumor immunity.
Gene Signatures of NK Cells and cDC1 Positively Correlate with Cancer Patient Survival
Finally, we assessed the degree to which these observations related to disease outcome. Notably, higher expression of NK signature genes in tumor samples ( Figures 7A and 7B ) was significantly associated with patient survival in all cancer types ( Figure 7C ; Table S1 ). Similarly, stratification of patients by expression of cDC1-associated genes ( Figures 7D and 7E) indicated that a higher cDC1 signature in tumors is positively associated with survival ( Figure 7F ; Table S1 ). Of note, a single cDC1 marker, CLEC9A, was also prognostic of patient survival (Figure 7G ) and the cDC1 signature was at least as powerful a predictor of cancer patient survival as a CD8 T cell signature ( Figure 7H ). Consistent with the analyses in TCGA datasets, we found a similar positive correlation of NK cell and cDC1 gene signatures in an independent cohort of breast cancer patients (Figures S7A and S7B) in which cancers were further classified into clinical groups, including the triple-negative breast cancer subtype (TNBC) that has poor prognosis. Strikingly, TNBC samples showed a very significant positive association between cDC1 and NK cell signature genes and survival ( Figures S7A and  S7B) , which was even more pronounced than when all breast cancer patients were analyzed without separating by tumor subgroup. Altogether, these data indicate across a wide array of human tumors that those with the highest NK cell and cDC1 content display the best prognosis. Importantly, high NK cell and cDC1 content was not merely a proxy for cancers with high overall immune infiltration as expression of monocyte/ macrophage-specific genes such as CD68 or CD14 in tumor samples was not positively correlated with patient survival in any type of cancer ( Figure S7C and data not shown) . Thus, our analysis reveals the importance of the quality rather than the quantity of the immune infiltrate and the favorable consequences of NK cell and cDC1 recruitment.
Similar to the analyses of cDC1 and NK cell gene signatures, we observed a positive correlation with survival when we ranked melanoma, HNSC and TNBC patients according to expression of CCL5, XCL1, and XCL2 ( Figures S7D and S7E) . However, in lung and breast cancer, with the exception of TNBC, the association between higher chemokine signature and survival did not reach significance ( Figure S7D ), despite them all displaying an association of survival with cDC1 signatures. This discrepancy is likely due to chemokine redundancy and additional mechanisms contributing to the accumulation of cDC1 within some tumors. Finally, it is possible that pleiotropic chemokines such as CCL5 can contribute to tumor progression by recruiting regulatory T cells (Velasco-Velá zquez et al., 2014), obscuring the prognostic value of the three chemokine signature (data not shown).
DISCUSSION
Myeloid cells such as macrophages and DCs within the TME shape tumor development and anti-cancer immunity. cDC1 fulfill a unique role in promoting the latter through their ability to transport tumor antigens to tumor draining LNs for T cell priming, to produce chemokines that recruit T cells into the TME, and to locally secrete IL-12 and restimulate tumor-infiltrating T cells. Because of these functions, the abundance of intratumoral cDC1s in tumors has previously been suggested to correlate with immune-mediated control and favorable outcome in both mice and humans (Broz et al., 2014; Salmon et al., 2016; Spranger et al., 2015 Spranger et al., , 2017 . However, the mechanisms that control the accumulation of cDC1 within tumors remain poorly understood. Here, we uncover a key role for NK cells in the production of chemoattractants, including CCL5 and XCL1/2, that are necessary for the accumulation of cDC1 in incipient tumors and for tumor immune control. We also show that this axis can be subverted by tumor-derived PGE 2 , which both impairs NK cell function and causes downregulation of the XCR1 and CCR5 chemokine receptors on cDC1. Finally, we suggest that intratumoral cDC1 accumulation in human tumors is regulated by a (legend on next page) similar mechanism as in mice and is positively correlated with favorable patient outcome in several different types of cancer. These findings illuminate the early events leading to tumor immunity and uncover a new checkpoint in immunity that could form the basis for novel cancer immunotherapies and for improving current ones.
NK cells contribute to anti-tumor immunity in mice and are associated with good prognosis in human cancer patients (Palucka and Coussens, 2016; Vesely et al., 2011) . They can secrete cytostatic cytokines such as interferon gamma (IFN-g) and can directly kill tumor cells, functions that render NK cells an attractive potential target for immunotherapy. Our analyses indicate an additional, so far unrecognized, function of NK cells in the recruitment of cDC1 into the TME. Interestingly, exclusion of cDC1 in lung adenocarcinoma has been reported to coincide with a lack of intratumoral NK cells (Lavin et al., 2017) , independently supporting the idea that NK cells contribute to the accumulation of cDC1 in tumors. At the same time, our data raise the question of how NK cells recognize tumor cells and accumulate within incipient tumors. Cells undergoing neoplastic transformation often show increased expression of ligands for NK cell activating receptors (Diefenbach et al., 2001; Gasser et al., 2005) , which endow NK cells with the ability to participate in tissue stress surveillance responses (Hayday, 2009; Raulet and Guerra, 2009 ). Therefore, activation of NK cell receptors by ligands expressed by transformed cells might be key for innate anti-tumor immunity and, as revealed here, also sets in motion adaptive immunity through production of cDC1 chemoattractants. Consistent with this notion, stimulation of the activating receptor NK1.1 on NK cells in vitro resulted in secretion of both CCL5 and XCL1. However, the degree to which activating ligands expressed by cancer cells versus additional signals (e.g., from cytokines such as type I IFNs or IL-15) (Delconte et al., 2016) contribute to NK cell-dependent ignition of anti-cancer immunity remains to be elucidated.
Although fully differentiated cDC1 can be detected in blood, especially in humans, cDC1 that accumulate in tissues in steady-state are thought to develop from committed precursors (pre-cDC1) that originate in bone marrow and travel via blood to seed peripheral organs (Grajales-Reyes et al., 2015; Liu et al., 2009; Schlitzer et al., 2015) . However, it is not known whether ''emergency'' needs for cDC1, such during tumor development, are met by increased pre-cDC1 recruitment. Notably, pre-cDC1 do not express the chemokine receptors XCR1 or CCR5 (Grajales-Reyes et al., 2015), implying that they cannot respond to CCL5 and XCL1 secreted by intratumoral NK cells. Similarly, the steady-state tissue colonization of tissues by DCs is NK cell-independent. Therefore, while it will be important to investigate the degree to which pre-cDC1 might be selectively recruited to tumors, our findings, including from ex vivo migration assays, suggest that the NK cell-dependent cDC1 accumulation could additionally rely on the recruitment and/or retention of differentiated cDC1, either from the circulation or surrounding tissue.
In murine tumors, intratumoral cDC1 were located in very close proximity to NK cells and both cell types were often situated in multicellular clusters within the TME. It seems likely that these clusters are a result of the chemotactic cues provided by NK cells, but might additionally be supported by chemokines secreted by cDC1 (e.g., CXCL9 and CXCL10) that could attract NK cells via CXCR3 (Spranger et al., 2017; Wendel et al., 2008) . The observed clustering of cDC1 and NK cells within the TME might ensure further communication between these two cell types, eventually leading to mutual activation of cDC1 and NK cells and facilitating anti-tumor immunity, similar to reciprocal activation of cDC1 and XCL1-secreting T cells in lymph nodes and within the intestine (Brewitz et al., 2017; Ohta et al., 2016) . Consistent with this possibility, a very recent study suggests that cDC1-derived IL-12 is essential for the anti-tumor activity of NK cells (Mittal et al., 2017) while NK cell-derived IFN-g sustains production of IL-12 by cDC1 (Alexandre et al., 2016) . Nevertheless, it is possible that, in some instances, infiltrating T or other cells producing CCL5, XCL1, and/or XCL2 can substitute for NK cells in maintaining the recruitment of cDC1.
The generation of PGE 2 by elevated COX activity is a mechanism by which tumors can evade anti-tumor immunity (Zelenay et al., 2015) . Our results indicate that a key target of PGE 2 is NK cells, which fail to accumulate in PGE 2 -producing tumors and are further impaired in their survival and ability to produce CCL5 and XCL1. PGE 2 likely has additional effects on NK cells, such as inducing the downregulation of NK cell activatory receptors or cytotoxic effector molecules (Kalinski, 2012) . In addition, autocrine PGE 2 decreases the expression of activating NK cell receptor-ligands on tumor cells (Pietra et al., 2012) . However, in addition to targeting NK cell activity, PGE 2 also hinders cDC1 directly, by causing downregulation of the chemokine receptors that promote recruitment into tumors. Therefore, PGE 2 impairs anti-tumor immunity by acting on at least two cellular layers of the innate immune system, NK cells and cDC1. In addition, PGE 2 is known to also directly suppress cytotoxic T cell action Su et al., 2011) underscoring its role as a major immunosuppressive mediator that interferes with multiple aspects of anti-cancer immunity. See also Figure S7 and Table S1 .
In a previous study, the ratio between transcripts from a set of genes enriched in cDC1 and levels of transcripts expressed by other myeloid cells proved to be a prognostic marker for cancer patient survival (Broz et al., 2014) . Furthermore, CCR7 transcript levels in a cohort of melanoma patients correlated with survival, pointing to a potential role for CCR7-expressing cells, including cDC1, in anti-tumor immunity (Roberts et al., 2016) . However, the transcripts used in those studies are not entirely selective for cDC1 and, therefore, we derived a new cDC1 gene signature based on the transcriptome of DC subsets across several human tissues (Heidkamp et al., 2016) . The selectivity of the cDC1 signature described here was independently confirmed in a recent unbiased genomic profiling of human DC subsets and monocytes by single-cell RNA-sequencing, which established cDC1-restricted expression of CLEC9A, XCR1, CLNK, and BATF3 (Villani et al., 2017) . This new cDC1 signature provides a powerful means to demonstrate a positive association of cDC1 with patient survival in several human cancers, including metastatic melanoma, breast cancer, head and neck squamous cell carcinoma, and lung adenocarcinoma. Interestingly, CLEC9A as a single cDC1-specific marker showed almost identical prognostic value in these analyses, underscoring the strong discriminatory power of CLEC9A in identifying cDC1 in tissues, as recently confirmed (Villani et al., 2017) . We therefore propose that CLEC9A should be used for assessing cDC1 content in tumors, either as a single marker or in combination with other strictly cDC1-specific genes such as XCR1. However, XCR1 expression on intratumoral cDC1 has to be carefully evaluated, given our observation that tumor-derived PGE 2 can induce its downregulation.
Similar to cDC1 in mice, human cDC1 seem to be very rare in tumors and are often excluded from samples associated with tumor progression (Lavin et al., 2017) . In line with this, we found a very low abundance of cDC1-specific transcripts in some TCGA datasets such as colorectal cancer, precluding us to evaluate the role of cDC1 in that cancer (data not shown). Interestingly, key enzymes for PGE 2 production such as COX-2 are often overexpressed in colorectal cancer and associated with poor prognosis (Dannenberg and Subbaramaiah, 2003) , suggesting that PGE 2 might be one of the mechanism responsible for the scarcity of cDC1 in the TME of some human tumors. In line with this, we detected a significant negative correlation between the transcript levels of PTGS2 and XCL1 or XCL2 in some but not all the TCGA patient datasets analyzed in our study (data not shown). Further studies are necessary to determine the exact contribution of PGE 2 to cDC1 scarcity in human cancer.
Our findings on the interplay between NK cells and cDC1 within the TME have several therapeutic implications. First, our analyses of human cancer samples clearly establish that dearth of cDC1 is associated with poor prognosis of patient outcome, as previously suggested (Broz et al., 2014) . This implies that cDC1 have a role in spontaneous anti-tumor immunity in humans, as in mice. Given that intratumoral cDC1 are also essential for T cell-based therapies in mouse tumor models (Broz et al., 2014; Salmon et al., 2016; Sá nchez-Paulete et al., 2016; Spranger et al., 2015) , our data further indicate that a low frequency of cDC1 might be one reason for the low response rate of cancer patients to immune checkpoint blockade. It would be of great interest to establish whether cDC1 accumulation (e.g., determined by assessing cDC1-specific transcripts such as CLEC9A) can serve as a predictive biomarker for the outcome of such treatments. Second, our data indicate that increasing the accumulation of intratumoral cDC1 enhances tumor immune control even in the absence of innate immune stimuli that deliberately promote cDC1 activation. Locally stimulating intratumoral NK cells or developing XCR1 ligands to attract cDC1 into the TME could be an attractive therapeutic means of eliciting anti-tumor immunity and increasing the response rate to immunotherapy. On this note, it seems intuitive to preferentially target the XCL1/XCL2-XCR1 axis rather than CCL5 to guide cDC1 into tumors, thereby ensuring that CCL5-mediated recruitment of tumor-promoting immune cells such as macrophages or regulatory T cells is avoided. Therapeutic strategies aiming to increase cDC1 numbers in tumors might benefit from combination with COX-inhibitors, especially in tumors that show high levels of PGE 2 production. Finally, it is likely that additional immunosuppressive mechanisms contribute to excluding NK cells and cDC1 from tumors. Identifying such factors may help develop new strategies to augment cDC1 recruitment into tumors and increase the fraction of patients benefiting from cancer immunotherapy.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Crick Institute under specific pathogen-free conditions. Mice were used at 6-12 weeks of age, gender-matched and littermates of the same sex were randomly assigned to treatment or control groups in all experiments. All animal experiments were performed in accordance with national and institutional guidelines for animal care and were approved by the Francis Crick Institute Biological Resources Facility Strategic Oversight Committee (incorporating the Animal Welfare and Ethical Review Body) and by the Home Office, UK.
Cell lines and primary cell cultures Mycoplasma negative BRAF V600E melanoma, CT26 colorectal cancer, 4T1 breast cancer, B16-OVA and GP2-293 cell lines were and cultured in complete RPMI medium (RPMI 1640 with 10% fetal calf serum, 50mM 2-mercaptoethanol, 100U/ml Penicillin, 100mg/ml Streptomycin, 292ng/ml L-Glutamin). COX-sufficient control and Ptgs1/Ptgs2 À/À cell lines were generated by CRISPR/Cas9-mediated gene editing as described previously (Zelenay et al., 2015) . In vitro differentiation of CD103 + cDC1 was performed with primary bone marrow cells from female C57BL/6 mice at 6-12 weeks of age using the induced CD103 DC protocol (Mayer et al., 2014) . DCs were harvested 12-14 days after the start of the culture and used for experiments.
METHOD DETAILS
Tumor cell injections Cells were harvested by trypsinization and washed three times in PBS. 2x10 5 or 2x10 6 cells were injected s.c. in 100ml endotoxin-free PBS on the flank of recipient mice. Tumor growth was measured using a digital caliper. Tumor diameters stated in the figures refer to the average of the longest diameter and its perpendicular for each tumor.
NK cell depletion in vivo
For depletion of NK cells, mice were injected i.p. with 100ml of an antibody cocktail containing anti-NK1.1 (clone PK136, 40mg/mouse) and anti-Asialo-GM1 (Poly21460, Biolegend, 35ml/mouse) one day prior and one day after tumor transplantation. For tumor growth experiments, antibody injections were performed every 3-4 days during the course of the experiment.
Chemokine neutralization in vivo
For neutralization of CCL5 and XCL1, 50mg of anti-CCL5 and 50mg of anti-XCL1 antibodies or of isotype-matched control antibodies were injected i.v. at the time of tumor transplantation, followed by a second injection two days later (R&D Systems; CCL5: AF478 and MAB478; XCL1: AF486, MAB486; Isotype controls: AB-108-C, MAB006).
Processing of tumor tissue
Unless stated otherwise, tumors were excised 4 days after transplantation. Mammary tumors from female MMTV-PyMT mice were excised when palpable. Tumor mass of individual tumors was determined using a microscale. For subsequent analysis by flow cytometry, tumors were cut into pieces and digested with Collagenase IV (200U/ml) and DNase I (100mg/ml) for 30min at 37 C. Tissue was passed through a 70mm cell strainer (Falcon) and washed with FACS buffer (PBS with 1% FCS and 2mM EDTA) before proceeding with antibody mediated staining. For protein/chemokine analyses, tumors were placed in protein lysis buffer (PBS with Aprotinin, Leupeptin and Pepstatin (all 10mg/ml)) and homogenized using a TissueLyser II (QIAGEN). For RNA isolation, homogenization was performed in RLT buffer (QIAGEN).
Chemokine analyses
Total protein content of tumor lysates was quantified by bicinchoninic acid (BCA) assay (Thermo Fisher Scientific). Profiling of intratumoral chemokines was done for 500mg protein from tumor lysates using the Mouse Chemokine Array Kit (R&D Systems) according to the manufacturer's instructions. Signal was revealed by SuperSignal West Pico Chemiluminescent substrate (Thermo Fisher Scientific); and signal of individual chemokine spots was quantified using ImageJ software. Quantification of chemokines in tumor lysates or from cell culture supernatants was done by flow cytometry using the Cytometric Bead Array (CBA, BD Biosciences). Detection of XCL1 protein in cell culture supernatants was done by ELISA (R&D Systems). Note that the lack of sensitivity of this ELISA precluded analysis of XCL1 protein in tumor extracts.
Dendritic cell migration assays
Chemotaxis of cDC1 was analyzed in transwell migration assays. 5x10 5 DCs were taken up in RPMI/1% BSA and placed into 5mm pore size transwell inserts (Corning), which were placed into wells of a tissue culture plate containing 500ml RPMI/1% BSA ± 100ng/ml CCL5 (R&D) or 150ng/ml XCL1 (R&D). After incubation at 37 C for 2h, cells in the lower compartment were harvested and quantified by flow cytometry. Migration was calculates as % live cells in bottom well relative to input.
NK cell stimulation assays NK cells were purified from spleens or Ptgs1/Ptgs2 À/À BRAF V600E tumors of wild-type C57BL/6J mice by negative selection using the NK Cell Isolation Kit II (Miltenyi Biotec). NK cells were cultured at 37 C in medium containing either 200U/ml recombinant IL-2, 5ng/ml IL-15 or 5ng/ml IL-15:IL-15Ra complexes (Invitrogen) for 16h. To assess chemokine production, NK cells were stimulated with platebound anti-NK1.1 antibody (PK136) for 16h. Where indicated, 1-100ng/ml PGE 2 (Sigma) was added to the in vitro culture.
Flow cytometry and fluorescence activated cell sorting Flow cytometric analyses were performed using an LSR Fortessa, LSR Fortessa X20 or FACSymphony (BD Biosciences). Data were analyzed using FlowJo (Tree Star). DAPI (0.5 mg/ml, Sigma-Aldrich) or a Live/Dead fixable cell stain kit (Invitrogen) was used to exclude dead cells in all experiments, and anti-CD16/CD32 antibody (2.4G2) was used to block non-specific binding of antibodies via Fc receptors. The following antibodies were used for flow cytometry: anti-CD3ε (clone 17A2), anti-CD4 (RMA4.5), anti-CD8a (53-6.7), anti-CD8b (53-5.8), anti-CD11b (M1/70), anti-CD11c (N418), anti-CD16/CD32 (2.4G2), anti-CD24 (M1/69), anti-CD45.2 (104), anti-CD49a (HMa1), anti-CD49b (DX5) anti-CD64 (X54-5/7.1) anti-CD103 (M290), anti-Clec9a/DNGR-1 (1F6), anti-CCL5 (2E9/CCL5), anti-MHC class II (MHC II) I-a/I-E (M5/114.15.2), anti-NK1.1 (PK136), anti-PD-1 (29F.1A12), anti-TCRb (H57-597), anti-TCRgd (GL3), anti-TIM-3 (RMT3-23) and anti-XCR1 (ZET). Detection of cell death was done using the Annexin V Apoptosis Detection Kit with PI (Biolegend) according to the manufacturer's instructions. NK cells were identified as live CD45 numbers by flow cytometry was done using fluorescent beads (Beckman Coulter). For intracellular staining of CCL5 ex vivo, tumor-bearing mice were injected with brefeldin A (10mg/kg body weight) i.v. and tumors were collected 6h later. Tumor processing was done in presence of brefeldin A (5mg/ml) and cells were fixed in 4% paraformaldehyde for 10min at room temperature. Detection of intracellular mRNA encoding for XCL1 was done by PrimeFlow RNA Assay (Affymetrics and Thermo Fisher Scientific) using a type 1 probe according to the manufacturer's instructions. Intracellular staining was performed in permeabilization buffer (eBioscience) for 30min and cells were subsequently analyzed by flow cytometry. Staining of intracellular IRF8 (V3GYWCH) or Granzyme B (antihuman, cross-reactive with mouse, clone GB11) was done using the Foxp3/Transcription factor staining buffer set from eBioscience. All antibodies were purchased from Biolegend, BD Biosciences or eBioscience except for anti-DNGR-1, which was produced in house. Sorting of tumor cells after retroviral transduction was done using a BD FACSAria or a BD FACSAria Fusion. Purity of cell populations was determined by reanalysis of a fraction of sorted cell samples.
Immunofluorescence Imaging
Tumors were fixed in Antigenfix solution (Diapath). Samples were dehydrated in 30% sucrose prior to embedding in TissueTek OCT freezing medium (Sakura Finetek) and stored at À80 C. 30mm sections were permeabilized, blocked, and stained in 0.1M Tris (AppliChem) supplemented with 1% BSA, 0.3% Triton X-100 (Gerbu Biotechnik) and normal mouse serum (Life Technologies). Serial tumor sections were prepared and visually inspected by epifluorescence light microscopy before acquisition of representative areas by confocal microscopy. Staining used the following antibodies: anti-CD31 (clone Mec13.3; Biolegend), anti-CD103 (goat polyclonal; R&D Systems), anti-Collagen IV (rabbit polyclonal; Abcam), anti-NK1.1 (PK136; BD Biosciences), anti-MHC class II (MHCII) I-A/I-E (M5/114.15.2; BD Biosciences). Stained sections were mounted in Mowiol and analyzed on a LSM 710 or LSM 780 confocal microscope (Zeiss). Image analysis was performed using Imaris software (Bitplane) on maximum projections of 7-10 Z-plane sections. Semi-automated analyses using the Imaris surface generation tool was used to reconstruct surfaces for CD103 + cDC1,
CD103
À MHCII + cells, NK cells and CD31 + blood vessels. To calculate the distance of cells to the tumor margin, a surface outlining the margin of the tumor was generated based on Collagen IV staining. Automated quantification of the minimal distances between individual cells, of cells to CD31 + blood vessels or the tumor margin was done using the Imaris distance transformation tool.
Cloning of retroviral vectors for XCL1 and CCL5 expression NK cells were isolated from spleen of C57BL/6 WT mice and NK cell mRNA was purified using RNeasy Mini Kit (QIAGEN). Total cDNA was prepared by reverse transcription and DNA was then amplified using the following primers: XCL1-Forward (BamHI) 5 0 -GGCCCG GGGATCCATGGATGAGACTTCTCCTCCT-3 0 and XCL1-Reverse (XhoI) 5 0 -CGGCCAACCGGCTCGAGTTACCCAGTCAGGGTTA-3 0 for XCL1; CCL5-Forward (BamHI) 5 0 -GGCCCGGGGATCCATGGATGAAGATCTCTGCAG-3 0 and CCL5-Reverse (XhoI) 5 0 -CGGCCA ACCGGCTCGAGCTAGCTCATCTCCAAATA-3 0 for CCL5. Both PCR products and the target vector pMSCV-IRES-mCherry (Addgene #52114) were then digested with XhoI and BamHI for 1h at 37 C and purified by gel extraction after agarose gel electrophoresis. Ligation was performed for 1h at room temperature using T4 DNA ligase (NEB). The ligation mix was then transformed into One Shot TOP10 chemically competent bacteria (Thermo Fischer Scientific) and plated on ampicillin containing LB-agar plates. Single colonies were then sequenced and used for plasmid isolation using the High speed Maxi Kit (QIAGEN).
Retroviral transduction
GP2-293 packaging cells were transfected with a mixture of GeneJuice (Novagen), VSV-G envelope protein-coding plasmid, and a pMSCV-IRES-mCherry plasmid coding for the desired protein or empty as control. On three consecutive days post-transfection, the pseudotyped virus-containing culture medium was harvested, filtered, supplemented with 8 mg/ml polybrene (Sigma-Aldrich), and immediately applied to target cells for spinfection by centrifugation (90min, 2500xg at room temperature). After the incubation, the medium was exchanged for fresh complete RPMI1640 medium. Target cells were passaged at least three times after retroviral transduction and analyzed for mCherry expression as a read out for transduction efficiency. Where necessary, cells were FACSsorted based on mCherry expression to ensure equal levels of transduction between different cell lines.
RNA isolation and quantitative real-time PCR RNA was isolated using QIAGEN RNeasy Mini Kit and cDNA was synthesized using the Superscript II reverse transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) analysis was performed using Fast SYBR Green Master Mix (Invitrogen) according to the manufacturer's instructions on an QuantStudio (Thermo Fisher Scientific) using the relative standard curve method. The PCR conditions were 2min at 50 C, 10min at 95 C followed by 40 2-step cycles of 15 s at 95 C and 1 min at 60 C. Primers for XCL1 (Xcl1-Forward 5 0 -CTTTCCTGGGAGTCTGCTGC-3 0 and Xcl1-Reverse 5 0 -CAGCCGCTGGGTTTGTAAGT-3 0 ) and HPRT (HPRT-Forward 5 0 -TCAGTCAACGGGGGACATAAA-3 0 and HPRT-Reverse 5 0 -GGGGCTGTACTGCT-3 0 TAACCAG) as normalization control were used to assess relative gene expression.
Analysis of gene expression data
Publically available datasets were downloaded from gene expression omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). Affymetrix arrays were normalized using RMA. Illumina arrays were quantile normalized and log2 transformed. All data from expression arrays were processed within R. Data from the following gene expression datasets were used in this paper: GSE15907, GSE24759, GSE77671. For analyses of chemokines expressed by NK cells (GSE15907), analyses were restricted to probes with expression values above the standard post-normalization threshold of 120 indicating expression above background.
Bioinformatic analysis of cancer patient data RSEM normalized expression datasets from The Cancer Genome Atlas (TCGA) were downloaded from Firehose (https://gdac. broadinstitute.org/). Hierarchical clustering of expression data was plotted as heatmaps using the 'gplots' package (version 3.0.1), where red indicates higher and blue indicates lower expression relative to the mean expression per gene. For generation of gene expression signatures, normalized expression values were log2-transformed and ranked by the mean expression value of signature genes. The following gene signatures were used: chemokines (XCL1, XCL2, CCL5), NK cells (NCR1, NCR3, KLRB1, CD160, PRF1), cDC1 (CLEC9A, XCR1, CLNK, BATF3) and CD8 T cells (CD8A, CD8B, CD3E). Overall survival analyses were performed for the top and bottom quartile expression ranked values for selected genes or the ranked sum expression of gene signature and plotted for Kaplan-Meier curves using GraphPad Prism (GraphPad). Gene signature analyses for another cohort of breast cancer (including TNBC) patients were done using the KM plotter software (http://kmplot.com) (Szá sz et al., 2016) .
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis
All statistical analyses were performed using GraphPad Prism software (GraphPad). Statistical significance was determined using an unpaired two-tailed Student's t test. Statistical analyses for three or more groups and tumor growth profiles were done by ANOVA. Correlation analyses were performed using Pearson correlation. The log-rank (Mantel-Cox) test was used to determine statistical significance for overall survival in cancer patient data from TCGA. Data are shown as mean ± SD or mean ± SEM as indicated in the figure legends. Significance was assumed with *p < 0.05; **p < 0.01; ***p < 0.001. Pooled data from at least two independent experiments are shown in A-D and G, H and depicted as mean of all mice per group ± SEM. Representative data from one of at least three independent experiments are shown in E, F, I and J and depicted as mean per duplicate wells or mice per group from one experiment ± SD. (A and B) Survival analyses of a human breast cancer patient cohort with associated gene expression data available at the KM plotter site (http://kmplot.com). All breast cancer patients from the dataset or a sub-group of patients diagnosed with triple-negative breast cancer (TNBC) were split into the top and bottom half for expression of signature genes and compared for overall survival. (A) Prognostic value of a cDC1 signature (CLNK, BATF3, XCR1) for all breast cancer patients (n = 1764) or TNBC patients (n = 161). Please note that CLEC9A transcript is absent in this particular dataset and cannot be included in the signature. (B) Prognostic value of a NK cell signature (NCR1, NCR3, KLRB1, CD160, PRF1) for all breast cancer patients (n = 3951) or patients with TNBC (n = 255). (C) Prognostic value of CD68 expression levels in tumor biopsies for overall survival of human cancer patients from TCGA datasets. (D and E) Prognostic value of a chemokine signature (XCL1, XCL2 and CCL5) for overall survival of human cancer patients from (D) TCGA datasets as indicated or (E) human breast cancer patients available at the KM plotter site. p = p value, n = number of data points in the analysis.
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